Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

Mutations in LRRK2 as a cause of Parkinson's disease.

Giasson BI, Van Deerlin VM.

Neurosignals. 2008;16(1):99-105. Epub 2007 Dec 5. Review.

PMID:
18097165
2.

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium.

Lancet Neurol. 2008 Jul;7(7):583-90. doi: 10.1016/S1474-4422(08)70117-0. Epub 2008 Jun 6.

3.

The biology and pathobiology of LRRK2: implications for Parkinson's disease.

Moore DJ.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S92-8. doi: 10.1016/j.parkreldis.2008.04.010. Epub 2008 Jul 7. Review.

PMID:
18602856
5.

Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.

Tan EK, Skipper L, Chua E, Wong MC, Pavanni R, Bonnard C, Kolatkar P, Liu JJ.

Mov Disord. 2006 Jul;21(7):997-1001.

PMID:
16602113
6.

LRRK2 pathobiology in Parkinson's disease.

Martin I, Kim JW, Dawson VL, Dawson TM.

J Neurochem. 2014 Dec;131(5):554-65. doi: 10.1111/jnc.12949. Epub 2014 Oct 10. Review.

7.

LRRK2 in Parkinson's disease: protein domains and functional insights.

Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA.

Trends Neurosci. 2006 May;29(5):286-93. Epub 2006 Apr 17. Review.

PMID:
16616379
8.

A trojan horse for Parkinson's disease.

Hu Y, Tong Y.

Sci Signal. 2010 Apr 6;3(116):pe13. doi: 10.1126/scisignal.3116pe13. Review.

PMID:
20371768
9.

Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease.

Bardien S, Lesage S, Brice A, Carr J.

Parkinsonism Relat Disord. 2011 Aug;17(7):501-8. doi: 10.1016/j.parkreldis.2010.11.008. Review.

PMID:
21641266
10.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
11.

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, Markova ED, Limborska SA, Ivanova-Smolenskaya IA.

Eur J Neurol. 2007 Apr;14(4):413-7.

PMID:
17388990
12.

Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.

Anfossi M, Colao R, Gallo M, Bernardi L, Conidi ME, Frangipane F, Vasso F, Puccio G, Clodomiro A, Mirabelli M, Curcio SA, Torchia G, Smirne N, Di Lorenzo R, Maletta R, Bruni AC.

J Alzheimers Dis. 2014;38(2):351-7. doi: 10.3233/JAD-130689.

PMID:
23963289
13.

Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.

Whaley NR, Uitti RJ, Dickson DW, Farrer MJ, Wszolek ZK.

J Neural Transm Suppl. 2006;(70):221-9. Review.

PMID:
17017533
14.

A study of LRRK2 mutations and Parkinson's disease in Brazil.

Pimentel MM, Moura KC, Abdalla CB, Pereira JS, de Rosso AL, Nicaretta DH, Campos M Jr, de Almeida RM, dos Santos JM, Bastos IC, Mendes MF, Maultasch H, Costa FH, Werneck AL, Santos-Rebouças CB.

Neurosci Lett. 2008 Mar 5;433(1):17-21. doi: 10.1016/j.neulet.2007.12.033. Epub 2007 Dec 23.

PMID:
18201824
15.

Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.

Perez-Pastene C, Cobb SA, Díaz-Grez F, Hulihan MM, Miranda M, Venegas P, Godoy OT, Kachergus JM, Ross OA, Layson L, Farrer MJ, Segura-Aguilar J.

Neurosci Lett. 2007 Jul 18;422(3):193-7. Epub 2007 Jun 17.

16.

Biochemical and pathological characterization of Lrrk2.

Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM.

Ann Neurol. 2006 Feb;59(2):315-22.

PMID:
16437584
17.

Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.

Luzón-Toro B, Rubio de la Torre E, Delgado A, Pérez-Tur J, Hilfiker S.

Hum Mol Genet. 2007 Sep 1;16(17):2031-9. Epub 2007 Jun 20.

PMID:
17584768
18.

Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.

Gómez-Suaga P, Fdez E, Fernández B, Martínez-Salvador M, Blanca Ramírez M, Madero-Pérez J, Rivero-Ríos P, Fuentes JM, Hilfiker S.

Neuropharmacology. 2014 Oct;85:45-56. doi: 10.1016/j.neuropharm.2014.05.020. Epub 2014 May 24. Review.

PMID:
24863040
19.

LRRK2 Parkinson's disease: from animal models to cellular mechanisms.

Lin CH, Tsai PI, Wu RM, Chien CT.

Rev Neurosci. 2011;22(4):411-8. doi: 10.1515/RNS.2011.036. Epub 2011 Jun 17. Review.

PMID:
21679126
20.

Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.

Huang Y, Halliday GM, Vandebona H, Mellick GD, Mastaglia F, Stevens J, Kwok J, Garlepp M, Silburn PA, Horne MK, Kotschet K, Venn A, Rowe DB, Rubio JP, Sue CM.

Mov Disord. 2007 May 15;22(7):982-9.

PMID:
17427941

Supplemental Content

Support Center